心玮医疗-B(06609)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06609 心玮医疗-B

已收盘 02-09 16:08:04

43.650

+1.950

+4.68%

最高43.500	最低41.750	成交量1.36万
今开42.000	昨收41.700	日振幅4.20%
总市值16.95亿	流通市值13.78亿	总股本3,883万
成交额58.56万	换手率0.04%	流通股本3,157万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06609","market":"HK","secType":"STK","nameCN":"心玮医疗-B","latestPrice":43.65,"timestamp":1675930084022,"preClose":41.7,"halted":0,"volume":13600,"delay":0,"floatShares":31565804,"shares":38834408,"eps":-6.7284813,"marketStatus":"已收盘","marketStatusCode":5,"change":1.95,"latestTime":"02-09 16:08:04","open":42,"high":43.5,"low":41.75,"amount":585580,"amplitude":0.041966,"askPrice":43.85,"askSize":600,"bidPrice":43.65,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-5.25545041188153,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1675992600000},"adr":0,"listingDate":1629388800000,"adjPreClose":41.7,"volumeRatio":0.413444,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06609/wiki","defaultTab":"wiki","newsList":[{"id":"2309355178","title":"心玮医疗-B盘中异动 下午盘快速下跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2309355178","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2309355178?lang=zh_CN&edition=full","pubTime":"2023-02-06 13:22","pubTimestamp":1675660976,"startTime":"0","endTime":"0","summary":"2023年02月06日下午盘13时22分，心玮医疗-B股票出现异动，股价急速下跌5.10%。截至发稿，该股报40.001港元/股，成交量7000股，换手率0.02%，振幅4.98%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。心玮医疗-B股票所在的医疗保健设备行业中，整体跌幅为1.07%。其相关个股中，佳兆业健康、润迈德-B、官酝控股涨幅较大，振幅较大的相关个股有佳兆业健康、润迈德-B、爱康医疗，振幅分别为18.06%、16.00%、10.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230206132256846d6034&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230206132256846d6034&s=b","is_publish_highlight":false},{"id":"2304095186","title":"【券商聚焦】高盛削心玮医疗－Ｂ(06609)目标价5% 因新冠负面影响下调三年收入预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2304095186","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2304095186?lang=zh_CN&edition=full","pubTime":"2023-01-20 10:32","pubTimestamp":1674181945,"startTime":"0","endTime":"0","summary":"高盛发研报指，近期该行与心玮医疗管理层进行了沟通。公司指12月22日-1月23日大范围新冠病毒感染对神经介入治疗带来负面影响（约为正常手术量的30%）。例如，在一些医院，医生只在急诊科对中风患者进行药物溶栓，而没有进一步进行机械取栓。管理层预计手术将在今年第二季度逐渐恢复，此时中风患者住院期间对新冠病毒感染的担忧应该得到缓解。基于考虑新冠病毒感染带来的负面影响，高盛将公司2022-24财年收入预测分别下调13%/36%/42%，并将目标价由80港元下调至76港元，维持买入评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301201032308406e3d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301201032308406e3d1&s=b","is_publish_highlight":false},{"id":"2304605335","title":"*高盛削心玮医疗－Ｂ(06609)目标价5%至76港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2304605335","media":"金吾资讯","top":-1,"share":"https://www.laohu8.com/m/news/2304605335?lang=zh_CN&edition=full","pubTime":"2023-01-20 09:31","pubTimestamp":1674178318,"startTime":"0","endTime":"0","summary":"高盛将心玮医疗－Ｂ(06609)目标价由80港元下调至76港元，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023012009320382526d0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023012009320382526d0d&s=b","is_publish_highlight":false},{"id":"2302830725","title":"心玮医疗-B盘中异动 早盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2302830725","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2302830725?lang=zh_CN&edition=full","pubTime":"2023-01-12 11:17","pubTimestamp":1673493478,"startTime":"0","endTime":"0","summary":"2023年01月12日早盘11时17分，心玮医疗-B股票出现异动，股价急速下挫5.05%。截至发稿，该股报41.401港元/股，成交量5250股，换手率0.02%，振幅4.70%。心玮医疗-B股票所在的医疗保健设备行业中，整体涨幅为0.19%。其相关个股中，鹰瞳科技-B、微创医疗、诺辉健康-B涨幅较大，振幅较大的相关个股有中国卫生集团、归创通桥-B、鹰瞳科技-B，振幅分别为12.61%、8.42%、6.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230112111759846d1ed9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230112111759846d1ed9&s=b","is_publish_highlight":false},{"id":"2294448505","title":"浙商证券： 冷冻消融板块或为国产弯道超车机会 建议关注微电生理(688351.SH)、惠泰医疗(688617.SH)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2294448505","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2294448505?lang=zh_CN&edition=full","pubTime":"2022-12-25 11:30","pubTimestamp":1671939041,"startTime":"0","endTime":"0","summary":"在冷冻消融方向，组套仅美敦力一家中标，配套采购中冷冻环形诊断导管仅心诺普与微创电生理两家中标。冷冻消融板块，或为国产弯道超车机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/852366.html","is_publish_highlight":false},{"id":"2291028577","title":"兼具成长价值双重属性，心玮医疗-B（6609.HK）估值重塑之路已现","url":"https://stock-news.laohu8.com/highlight/detail?id=2291028577","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2291028577?lang=zh_CN&edition=full","pubTime":"2022-12-16 16:02","pubTimestamp":1671177748,"startTime":"0","endTime":"0","summary":"近期，介入医疗器械领域两项收购引起了市场的极大关注。截至目前，公司已成功拥有16款治疗及预防脑卒中的医疗器械产品获批商业化。　　据悉，上半年心玮医疗取得收入7671.3万元，同比大增154.6%；净亏损为6698.5万元，同比收窄28.5%。自11月初以来，心玮医疗的股价从底部开始反弹，涨幅达超50%，正迎来估值修复。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hk.jrj.com.cn/2022/12/16160237218212.shtml","is_publish_highlight":false},{"id":"2285882004","title":"【券商聚焦】高盛维持心玮医疗-B(06609)“买入”评级 指管理层指引24财年盈亏平衡","url":"https://stock-news.laohu8.com/highlight/detail?id=2285882004","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2285882004?lang=zh_CN&edition=full","pubTime":"2022-11-22 12:05","pubTimestamp":1669089934,"startTime":"0","endTime":"0","summary":"高盛发布研究报告指出，近期该行与心玮医疗-B管理层进行了沟通，管理层预期在VBP以前迅速商业化获得市场份额，以及扩大制造保利润。管理层指引23财年销售同比增长100%，目标是在24财年实现盈亏平衡。该行指出，公司为神经介入耗材的VBP做好准备。1)加快进入医院，在VBP竞标前获得更多的市场份额；2)通过扩大连云港的生产能力，获得更好的规模经济效益；3)优化分销网络；4)更广泛的产品组合，以减轻单一产品类别的VBP风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=fc52d79d9954704deb60d2055d263821","is_publish_highlight":false},{"id":"2282907952","title":"心玮医疗-B(06609)临时股东大会及类别股东大会已通过A股发行相关议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2282907952","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2282907952?lang=zh_CN&edition=full","pubTime":"2022-11-09 22:46","pubTimestamp":1668005164,"startTime":"0","endTime":"0","summary":"智通财经APP讯，心玮医疗-B 公布，公司于2022年11月9日召开临时股东大会及类别股东大会，审议通过建议A股发行相关议案，并委任陈少雄为非执行董事，委任姜心贝及姜雪为监事。公司认为，在科创板上市将对公司及其股东整体有利，有利于加强公司的可持续发展。于公司H股于2021年8月上市后，A股发行使该公司能够成为一间双重上市公司，进一步丰富其资本基础及开发国内外融资平台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/827463.html","is_publish_highlight":false},{"id":"2282902063","title":"心玮医疗-B(06609)：陈少雄获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2282902063","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2282902063?lang=zh_CN&edition=full","pubTime":"2022-11-09 22:35","pubTimestamp":1668004544,"startTime":"0","endTime":"0","summary":"心玮医疗-B(06609)发布公告，经股东于临时股东大会上批准，陈少雄获委任为非执...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_38.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_38.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/827458.html","is_publish_highlight":false},{"id":"2282913614","title":"智通港股投资日志|11月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2282913614","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2282913614?lang=zh_CN&edition=full","pubTime":"2022-11-09 00:00","pubTimestamp":1667923201,"startTime":"0","endTime":"0","summary":"港股投资日志|2022年11月9日","market":"hk","thumbnail":"https://img.zhitongcaijing.com/jqr/ggtzrl.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/jqr/ggtzrl.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/826420.html","is_publish_highlight":false},{"id":"2280516760","title":"智通港股投资日志|11月4日","url":"https://stock-news.laohu8.com/highlight/detail?id=2280516760","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2280516760?lang=zh_CN&edition=full","pubTime":"2022-11-04 00:00","pubTimestamp":1667491202,"startTime":"0","endTime":"0","summary":"智通财经APP统计，2022年11月4日，港股上市公司投资日志如下：    类别 公司  新股活动交运燃气(招股中)子不语(定价日)巨子生物(上市日) 业绩公布日高萌科技永续农业海天天线FIRST CREDIT宝燵控股优通未来易通讯集团亚势备份沛然环保扬宇科技 股东大会召开日广深铁路股份华侨城(亚洲)心玮医疗-B海普瑞十方控股创胜集团-B普甜食品 分红派息首钢资源（派息日）中原建业（派息日）合生创展集团（除净日）康师傅控股（除净日）华润电力（派息日）越秀交通基建（除净日）达丰设备（派息日）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/823439.html","is_publish_highlight":false},{"id":"2275939918","title":"心玮医疗-B盘中异动 下午盘急速下挫5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2275939918","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2275939918?lang=zh_CN&edition=full","pubTime":"2022-10-14 15:30","pubTimestamp":1665732601,"startTime":"0","endTime":"0","summary":"2022年10月14日下午盘15时30分，心玮医疗-B股票出现波动，股价大幅下挫5.75%。心玮医疗-B股票所在的医疗保健设备行业中，整体涨幅为0.94%。截至10月12日收盘，心玮医疗港股市值不到11亿人民币。排除未来公司发行股份和募资额变动的干扰，按A股最低发行25％公开股份计算，预估心玮医疗拟发行的市值超过57亿人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202210141530028468ceb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202210141530028468ceb9&s=b","is_publish_highlight":false},{"id":"2274513545","title":"心玮医疗-B拟发行A股于科创板上市 募资14.32亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2274513545","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2274513545?lang=zh_CN&edition=full","pubTime":"2022-10-11 08:26","pubTimestamp":1665447960,"startTime":"0","endTime":"0","summary":"心玮医疗-B（06609）发布公告，该公司建议向中国相关监管机构申请配发及发行不多于1300万股A股，以及建议向上海证券交易所申请批准A股在科创板上市及买卖。\n　　经扣除发行费用后，该公司自建议A股发行的募集资金总计人民币14.32亿元（单位下同）。其中，约8.4亿元将用于心玮医疗总部、高端医疗器械研发及产业化项目；约1.92亿元将用于营销服务及品牌建设项目；及4亿元将用于补充流动资金。\n\n炒股开户享福利，入金抽188元红包，100%中奖！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2022-10-11/doc-imqmmthc0449091.shtml?finpagefr=p_115","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2022-10-11/doc-imqmmthc0449091.shtml?finpagefr=p_115","is_publish_highlight":false},{"id":"2274518232","title":"心玮医疗-B(06609)拟发行A股于科创板上市，募资14.32亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2274518232","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2274518232?lang=zh_CN&edition=full","pubTime":"2022-10-11 08:14","pubTimestamp":1665447284,"startTime":"0","endTime":"0","summary":"智通财经APP讯，心玮医疗-B 发布公告，该公司建议向中国相关监管机构申请配发及发行不多于1300万股A股，以及建议向上海证券交易所申请批准A股在科创板上市及买卖。经扣除发行费用后，该公司自建议A股发行的募集资金总计人民币14.32亿元。于公司H股于2021年8月上市后，A股发行使该公司能够成为一间双重上市公司，进一步丰富其资本基础及开发国内外融资平台。在科创板上市有利于促进公司及股东的整体价值及利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/803451.html","is_publish_highlight":false},{"id":"2274175599","title":"心玮医疗(06609.HK)建议发行A股科创板上市  集资14亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2274175599","media":"AAFN","top":-1,"share":"https://www.laohu8.com/m/news/2274175599?lang=zh_CN&edition=full","pubTime":"2022-10-11 04:29","pubTimestamp":1665433762,"startTime":"0","endTime":"0","summary":"心玮医疗－Ｂ  公布，建议首次公开发行不多於1,300万股A股，并向上海证券交易所申请在科创板上市及买卖。估计募集14.32亿人民币，拟用於心玮医疗总部、高端医疗器械研发及产业化项目；营销服务及品牌建设项目；及补充流动资金。(de/d)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1218239&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false},{"id":"2274645265","title":"心玮医疗-B(06609.HK)拟申请科创板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2274645265","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2274645265?lang=zh_CN&edition=full","pubTime":"2022-10-10 23:05","pubTimestamp":1665414304,"startTime":"0","endTime":"0","summary":"格隆汇10月10日丨心玮医疗-B公告，公司建议向中国相关监管机构申请配发及发行不多于1300万股A股，以及建议向上海证券交易所申请批准A股在科创板上市及买卖。A股发行须待股东于临时股东大会及类别股东大会上通过特别决议案批准，以及于中国证监会和上海证券交易所批准后，方可作实。在科创板上市有利于促进公司及股东的整体价值及利益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hk.jrj.com.cn/2022/10/10230537045520.shtml","is_publish_highlight":false},{"id":"2270035054","title":"心玮医疗-B（6609.HK）：下一个百亿市值的Penumbra","url":"https://stock-news.laohu8.com/highlight/detail?id=2270035054","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2270035054?lang=zh_CN&edition=full","pubTime":"2022-09-26 08:46","pubTimestamp":1664153205,"startTime":"0","endTime":"0","summary":"心玮医疗自上市以来商业化进程不断加快，盈利能力以及成长能力不断体现。与同业指标进行对比，无论是往期营业收入表现还是在今年上半年需求放缓中的收入情况，都可以说拿到一流成绩单。","market":"us","thumbnail":"https://img2.gelonghui.com/431d1-ac05e0a0-b906-40b2-9bb9-a2ccf570ec78.png","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/431d1-ac05e0a0-b906-40b2-9bb9-a2ccf570ec78.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.gelonghui.com/p/553777","is_publish_highlight":false},{"id":"2265567037","title":"【券商聚焦】高盛下调心玮医疗-B(06609)目标价至106港元 料其业绩仍受疫情影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2265567037","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2265567037?lang=zh_CN&edition=full","pubTime":"2022-09-06 10:19","pubTimestamp":1662430772,"startTime":"0","endTime":"0","summary":"高盛发研报指，心玮医疗-B今年上半年销售额为7700万，同比增长155%，略高于该行预期的7200万，主因受益于疫情期间对缺血性卒中耗材的需求。毛利率为66.3%，同比增长306个基点，主要由规模经济提升推动，预计随着制造技术愈发成熟，毛利率将持续提升。净亏损录得6700万元，符该行预期；管理费用减少3800万元，同比收窄21%，主因股票奖励减少，抵消了同比增长88%至6100万元的较高研发费用。目标价从122港元下调13%至106港元，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=82117a72e4558e3cc18e20f1a3e9f615","is_publish_highlight":false},{"id":"2265031598","title":"*高盛削心玮医疗-B(06609)目标价13%至106港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2265031598","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2265031598?lang=zh_CN&edition=full","pubTime":"2022-09-06 08:54","pubTimestamp":1662425661,"startTime":"0","endTime":"0","summary":"高盛将心玮医疗-B(06609)目标价从122港元下调13%至106港元，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=8fc8951059e5848f13c35f3d0fbc613d","is_publish_highlight":false},{"id":"2264274370","title":"营收大增154.6%，心玮医疗-B（6609.HK）成长确定性持续增强","url":"https://stock-news.laohu8.com/highlight/detail?id=2264274370","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2264274370?lang=zh_CN&edition=full","pubTime":"2022-09-02 16:54","pubTimestamp":1662108893,"startTime":"0","endTime":"0","summary":"从此次心玮医疗的中期财报中也能看出，公司的未来发展兼具成长性和确定性。","market":"us","thumbnail":"https://img2.gelonghui.com/53916-a18b30b9-fcc1-48fa-8a2f-fc98375fc240.png","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/53916-a18b30b9-fcc1-48fa-8a2f-fc98375fc240.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.gelonghui.com/p/549872","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0747},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.4256},{"period":"6month","weight":0.1763},{"period":"1year","weight":-0.406},{"period":"ytd","weight":0.1347}],"websiteUrl":"http://www.strokemedical.com","compareEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.3235},{"period":"6month","weight":0.0549},{"period":"1year","weight":-0.1252},{"period":"ytd","weight":0.0759}],"name":"心玮医疗-B","description":null,"exchange":"SEHK","nameEN":"Shanghai HeartCare Medical Technology Corporation Limited","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.11.13","shortVersion":"4.11.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"心玮医疗-B(06609)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供心玮医疗-B(06609)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"心玮医疗-B,06609,心玮医疗-B股票,心玮医疗-B股票老虎,心玮医疗-B股票老虎国际,心玮医疗-B行情,心玮医疗-B股票行情,心玮医疗-B股价,心玮医疗-B股市,心玮医疗-B股票价格,心玮医疗-B股票交易,心玮医疗-B股票购买,心玮医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"心玮医疗-B(06609)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供心玮医疗-B(06609)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}